This site uses cookies to provide services, collect traffic data, and personalize ads. You agree by using this site.
More info
en
Press releases

NL Holding announces it has secured Oaktree Capital Management as its partner for further expansion and the acquisition

15.02.2018

NL Holding announces it has secured Oaktree Capital Management, a major global investment group, as its partner for further expansion and the acquisition of healthcare facilities in Spain, Italy, and Switzerland.

“The entry of Oaktree Capital Management, one of the world’s largest global investment groups, allows NL Holding to pursue its strategy of consolidating reproduction medical clinics in Europe and abroad,” says Miroslaw Herden, who has been named CEO and responsible for NL Holding’s further development. “Our strategic objective is to build a European network of modern clinical facilities for assisted reproduction, genetics and specialised laboratories and offer complementary services provided by out-patient facilities,” explains Miroslaw Herden.

NL Holding has extended its current portfolio of healthcare facilities it operates to include the ProCrea Group in Lugano which provides assisted reproduction services and specialised diagnostic services as well as plastic surgery and genetics for Swiss and international patients. ProCrea Group has facilities not only in Lugano, where it is based, but also in northern Italy. NL Holding has also acquired Archimed Group, an Italian centre for specialized genetics, laboratory and diagnostic services for more than 600 healthcare facilities.

NL Holding has recently also taken over IMER in Spain, a leader in egg donation in Europe. Its facilities in Valencia and Denia are considered one of the most modern facilities in the Iberian Peninsula providing genetics advice in addition to the standard services in assisted reproduction. IMER also operates facilities in Barcelona and is one of the leading supplier for assisted reproduction centres in Italy for egg donation.

“We acquired these facilities in order leverage synergic effects with our current assets and offer us growth in new regions,” adds Miroslaw Herden.

NL Holding: Further growth, seeking synergies, and development of assisted reproduction and related services

In 2018, NL Holding intends to invest up to 200 million Euro and will primarily target European and international reproductive and fertility facilities that feature innovative health care for patients and offer synergies with the growing portfolio. Over the past two years, NL Holding has invested in other facilities including hospitals, reproduction medicine clinics and also, for example, medical laboratories and a network of blood sampling and tissue collection centres in the Czech Republic, Italy, Germany, Spain, and Switzerland. In the Czech Republic, NL Holding operates an out-patient network, assisted reproduction centres and a network for genetic and special analytics and also offers direct sale of health services to clients via its unique Next Life system, which shall be implemented group wide in future. “We want to continue to reinforce all these activities. In doing so, we focus not only on the acquisition of facilities but also on the quality of the provided services and the mutual synergic effects that they bring,” says Josef Brož, Head of Advisory Board of NL Holding and invested in NL Holding.

NL Holding’s founding investors are from the Czech Republic, Italy, Germany, Spain and Switzerland. They want to build a strong partnership on their experience with the development of health care facilities and also on their practical experience with and knowledge of global healthcare operations. “We now see great potential in the consolidation of the market of reproduction medicine clinics and related services throughout Europe and their integration into a global network providing highly qualified specialist services at a high standard,” explains Miroslaw Herden, pointing out that in the Czech Republic and Germany, there are a large number of first-class experts with whom NL Holding already cooperates. “Further expansion of the network with those whom we work is the central source of how we plan to build our success,” adds Miroslaw Herden.

 

About us

NL - HOLDING is a dynamically growing healthcare company with headquarters in Germany. Entering the European market in 2015, its ambition was to foster innovative procedures in healthcare combining the latest diagnostic and treatment methods with a patient-centric approach and using high-tech communication technology. Our services are available in the Czech Republic, Italy, Germany, Spain and Switzerland, while also serving other countries.

NL - HOLDING is founded on three pillars, driven by the needs of today’s patients.  

NEXTCLINIC is a network of healthcare facilities with state-of-the art technology and instruments providing the most modern health services. Its success is built around working with high-quality physicians and experts with a patient-first approach.

NEXTLAB supplements these healthcare facilities with its own blood taking facilities and modern laboratories, which specialise in highly exacting and specialist examinations and genetic analysis and advice.

NEXTLIFE goes across all disciplines and offers patients comprehensive healthcare using advanced communication technology and interactive applications, ranging from preventive care to examination and potential treatment.



Back to overview

Other articles

NL Holding announces it has secured Oaktree Capital Management as its partner for further expansion and the acquisition

NL Holding announces it has secured Oaktree Capital Management, a major global investment group, as its partner for further expansion and the acquisition of healthcare facilities in Spain, Italy, and Switzerland.

NEXTCLINICS continues growing, the group acquired prominent assisted reproduction clinics in Northern Italy 

Bologna/Augsburg, 17 July 2018: In late June 2018, NEXTCLINICS acquired 100% of GynePro, an Italian medical Group with in-vitro fertilization (IVF) clinics located in Bologna and Verona. With a 20 year history, GynePro is a highly experienced and renowned medical group active in the area of infertility management, assisted reproductive technology (ART), and prenatal diagnosis. GynePro’s founder, Professor Dr. Marco Filicori, will remain with the clinic as its Medical Director and will become a shareholder and investor in NEXTCLINICS. This transaction strengthens NEXTCLINICS’ position as a leading pan European provider of ART clinics and laboratories. This is NEXTCLINICS’ first major transaction in 2018, and follows a number of late 2017 investments in leading fertility centers and laboratories across Europe, valued at 80 million Euro. The valuation of the GynePro transaction will not be disclosed.

Press releases overview...




NEXTCLINIC operates a network of modern and highly specialized healthcare facilities and offer care primarily in allergology, clinical immunology, pneumology, phtiseology as well as other related fields. We are a leading provider of assisted reproduction services (IVF), gynecology and obstetrics, and offer a diverse range of complimentary services. Our central fundamental guiding principle lies in a responsible and accountable approach to patients, one where information is shared, and where patients are encouraged to take an active role in their own wellbeing.

With presence on multiple European markets, NEXTCLINIC offers patients from around the world the opportunity to choose a preferred location and enjoy the benefits of unique destinations. Customers enjoy healthcare services, but also a wide range of complimentary services.

Project permeating across several disciplines, providing patients the ability to identify and integrate a whole new social group to gain many benefits. It creates opportunities for testing of your health and makes information about health and healthy lifestyle accessible.

The NEXTLIFE application change trends in patient communication with a physician. We allow quality and fast testing, where the patient can determine the time and method of examination. The NEXTLIFE magazine focuses on a healthy lifestyle.

NEXTLAB provides fast and accurate laboratory diagnostics on biological material for private GPs, outpatient specialists, hospitals, patients without a health insurance policy, and those who request laboratory services beyond standard testing.

NEXTLAB builds upon 20 years of experience with its own labs and sample collection centres, offering a wide range of lab tests based on the latest diagnostic methods, devices and technologies. Tests that are not carried out in our labs are forwarded to partner labs in compliance with a strict pre-analytical procedure.

You are leaving NEXTCLINICS website.

For more information about selected services, you will be redirected to %s.
Do you want to continue?

STAY ON THIS PAGE CONTINUE